These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

80 related items for PubMed ID: 18989348

  • 1. Sustained moderate visual loss as a predictive end point for visual loss in non-proliferative diabetic retinopathy.
    Girach A, Aiello LP, Milton RC, Davis MD, Danis RP, Zhi X, Sheetz MJ, Vignati L, PKC-DRS2 Study Group.
    Eye (Lond); 2009 Jan; 23(1):209-14. PubMed ID: 18989348
    [Abstract] [Full Text] [Related]

  • 2. Effect of ruboxistaurin (RBX) On visual acuity decline over a 6-year period with cessation and reinstitution of therapy: results of an open-label extension of the Protein Kinase C Diabetic Retinopathy Study 2 (PKC-DRS2).
    Sheetz MJ, Aiello LP, Shahri N, Davis MD, Kles KA, Danis RP, Mbdv Study Group.
    Retina; 2011 Jun; 31(6):1053-9. PubMed ID: 21386766
    [Abstract] [Full Text] [Related]

  • 3. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy.
    PKC-DRS2 GroupBeetham Eye Institute, Joslin Diabetes Center, 1 Joslin Place, Boston, MA 02215, USA. LPAiello@Joslin.Harvard.edu, Aiello LP, Davis MD, Girach A, Kles KA, Milton RC, Sheetz MJ, Vignati L, Zhi XE.
    Ophthalmology; 2006 Dec; 113(12):2221-30. PubMed ID: 16989901
    [Abstract] [Full Text] [Related]

  • 4. Oral protein kinase c β inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study 2.
    Aiello LP, Vignati L, Sheetz MJ, Zhi X, Girach A, Davis MD, Wolka AM, Shahri N, Milton RC, PKC-DRS and PKC-DRS2 Study Groups.
    Retina; 2011 Nov; 31(10):2084-94. PubMed ID: 21862954
    [Abstract] [Full Text] [Related]

  • 5. The effect of the oral PKC β inhibitor ruboxistaurin on vision loss in two phase 3 studies.
    Sheetz MJ, Aiello LP, Davis MD, Danis R, Bek T, Cunha-Vaz J, Shahri N, Berg PH, MBDL and MBCU Study Groups.
    Invest Ophthalmol Vis Sci; 2013 Mar 11; 54(3):1750-7. PubMed ID: 23404115
    [Abstract] [Full Text] [Related]

  • 6. Diabetic macular oedema and visual loss: relationship to location, severity and duration.
    Gardner TW, Larsen M, Girach A, Zhi X, Protein Kinase C Diabetic Retinopathy Study (PKC-DRS2) Study Group.
    Acta Ophthalmol; 2009 Nov 11; 87(7):709-13. PubMed ID: 19817721
    [Abstract] [Full Text] [Related]

  • 7. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial.
    PKC-DRS Study Group.
    Diabetes; 2005 Jul 11; 54(7):2188-97. PubMed ID: 15983221
    [Abstract] [Full Text] [Related]

  • 8. Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema.
    Davis MD, Sheetz MJ, Aiello LP, Milton RC, Danis RP, Zhi X, Girach A, Jimenez MC, Vignati L, PKC-DRS2 Study Group.
    Invest Ophthalmol Vis Sci; 2009 Jan 11; 50(1):1-4. PubMed ID: 18708615
    [Abstract] [Full Text] [Related]

  • 9. Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema.
    Sahu AK, Majji AB.
    Invest Ophthalmol Vis Sci; 2010 Dec 11; 51(12):6890; author reply 6890-1. PubMed ID: 21123772
    [No Abstract] [Full Text] [Related]

  • 10. A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy.
    Casellini CM, Barlow PM, Rice AL, Casey M, Simmons K, Pittenger G, Bastyr EJ, Wolka AM, Vinik AI.
    Diabetes Care; 2007 Apr 11; 30(4):896-902. PubMed ID: 17392551
    [Abstract] [Full Text] [Related]

  • 11. Ruboxistaurin: LY 333531.
    Drugs R D; 2007 Apr 11; 8(3):193-9. PubMed ID: 17472415
    [Abstract] [Full Text] [Related]

  • 12. The longitudinal link between visual acuity and health-related quality of life in patients with diabetic retinopathy.
    Matza LS, Rousculp MD, Malley K, Boye KS, Oglesby A.
    Health Qual Life Outcomes; 2008 Nov 07; 6():95. PubMed ID: 18992161
    [Abstract] [Full Text] [Related]

  • 13. Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications.
    Joy SV, Scates AC, Bearelly S, Dar M, Taulien CA, Goebel JA, Cooney MJ.
    Ann Pharmacother; 2005 Oct 07; 39(10):1693-9. PubMed ID: 16160002
    [Abstract] [Full Text] [Related]

  • 14. [Efficacy and safety of etofibrate in patients with non-proliferative diabetic retinopathy].
    Emmerich KH, Poritis N, Stelmane I, Klindzane M, Erbler H, Goldsteine J, Görtelmeyer R.
    Klin Monbl Augenheilkd; 2009 Jul 07; 226(7):561-7. PubMed ID: 19644802
    [Abstract] [Full Text] [Related]

  • 15. Visual outcome of laser treatment in diabetic retinopathy.
    Shrestha S, Karki DB, Byanju R, Malla OK, Shrestha SM, Pradhananga CL.
    Kathmandu Univ Med J (KUMJ); 2007 Jul 07; 5(1):72-80. PubMed ID: 18603990
    [Abstract] [Full Text] [Related]

  • 16. Complex deep lamellar endothelial keratoplasty for complex bullous keratopathy with severe vision loss.
    Huang T, Wang Y, Gao N, Wang T, Ji J, Chen J.
    Cornea; 2009 Feb 07; 28(2):157-62. PubMed ID: 19158557
    [Abstract] [Full Text] [Related]

  • 17. PKC inhibition and diabetic microvascular complications.
    Clarke M, Dodson PM.
    Best Pract Res Clin Endocrinol Metab; 2007 Dec 07; 21(4):573-86. PubMed ID: 18054736
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.